If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Geographical indications protect the name of a product that has a specific geographical origin and owes its qualities, characteristics or reputation to its particular origin. Find out what they are, how the registration process works and what benefits they provide.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
341
results.
Updated on
15/11/2026 [08:23:00]
Results 325 to 341 of 341
Absstract of: US20260275418A1
A method is disclosed for detecting schizophrenia, at any stage, which comprises the steps of determining the gene expression of ZNF560 in a biological sample from a subject and comparing it with the ones of a healthy individual as a control sample, wherein the subject of the biological sample is diagnosed as having schizophrenia the gene ZNF560 is overexpressed in the biological sample in comparison to the control. Also disclosed is a kit of parts to diagnose schizophrenia from a biological sample and the use of the kit of parts as a detection agent useful to diagnose schizophrenia, wherein schizophrenia could be at prodromal, acute, residual, or chronic stage.
Absstract of: WO2026189109A1
A high-sensitivity immunoassay method and system. The high-sensitivity immunoassay method for a target protein comprises: capturing the target protein to obtain a solution containing an immune complex; spreading said solution on a detection substrate under the action of a passive driving mechanism; immobilizing the immune complex on at least one surface; and performing detection and calculating the concentration of the immune complex. The immunoassay method uses a consumable structure having a simple structure and low costs, achieving highly sensitive detection of a target protein to be tested.
Absstract of: US20260276656A1
The present invention concerns new approaches for the diagnosis and treatment of dementia diseases. In particular, the present invention pertains to new markers for diagnosing dementia diseases as well as to new targets for the treatment of dementia diseases.
Absstract of: WO2026191421A1
Provided are a dementia diagnosis system and a dementia diagnosis program that are capable of identifying a patient having dementia with high accuracy by a simple and easy test. A dementia diagnosis system (1) has: a measurement unit (51) that continuously measures the acidity/basicity of a body fluid obtained from a subject; a confirmation unit (52) that confirms, for the acidity/basicity continuously measured by the measurement unit (51), an outlier at which the acidity/basicity becomes alkaline and the presence or absence of a change point at which the acidity/basicity persistently shifts to the alkaline side after the outlier is confirmed; and a prediction unit (53) that predicts whether or not the subject has dementia on the basis of the confirmation result of the confirmation unit (52).
Absstract of: WO2026193055A1
Described herein are humanized anti-ApoE antibody molecules, antigen-binding portions thereof, and uses thereof.
Absstract of: WO2026193298A1
Described herein is a method of diagnosing or predicting the risk of cognitive decline in a subject, and/or stratifying the subject according to the risk. The method comprises determining a profile of the subject; and predicting the risk based on the profile, or stratifying the subject to a high risk group or a low risk group based on the predicted risk. The profile comprises blood pressure; and the level of homocysteine (Hyc) in a biological sample from the subject. Also described herein is a method of treating, ameliorating, and/or preventing cognitive decline in the subject based on the prediction of the risk.
Absstract of: WO2026190495A1
The present invention refers to the field of in-vitro neural network stimulation, and particularly to devices that utilize cell cultures on multi-electrode arrays (MEAs) for investigating neuronal activity in research and drug testing applications. The invention consists of a closed loop system wherein a computational model stimulates via the electrodes of a MEA, cultured neurons on top of the MEA in order to produce disease- like activity states. The produced activity feeds back to the computational model, in real or periodic time, producing a hybrid neuronal population that can be used for drug screening. The respective method for the application of the abovementioned system is also disclosed.
Absstract of: WO2026190230A1
The present invention relates to alpha-synuclein antibodies which are useful in diagnostic assays for detecting aggregates, oligomers and fibrillar forms of alpha- synuclein in patient samples. These antibodies enable diagnosis and efficient treatment of alpha-synucleinopathies such as Parkinson's Disease (PD) or Multiple System Atrophy (MSA) patients by assessing and monitoring the pathological alpha-synuclein levels in patients.
Absstract of: US20260276657A1
Disclosed herein are antibodies, antibody fragments, binding agents, and compositions that specifically recognize protein variant biomarkers associated with frontotemporal dementia, kits and methods of use, including diagnosing, monitoring and treating frontotemporal dementia.
Absstract of: WO2026193412A1
Among other things, the present disclosure provides adenoviral vectors, genomes, and methods of use thereof. In some embodiments, the present disclosure provides methods of in vivo gene therapy comprising administration of an adenoviral payload vector and an adenoviral integration vector. The present disclosure provides, among other things, compositions comprising an adenoviral payload vector and an adenoviral integration vector for use in, e.g., methods of in vivo gene therapy. In some embodiments, the present disclosure provides adenoviral vectors, genomes, and compositions thereof comprising a therapeutic sequence, e.g., a nucleic acid sequence encoding a CYBB therapeutic polypeptide. In some embodiments, the present disclosure provides methods of treating various conditions, disorders, and diseases, e.g., chronic granulomatous disease.
Absstract of: WO2026193026A1
The invention provides methods for determining if a subject suffering from SARS-CoV-2 infection is susceptible to developing fibromyalgia. Also provided herein are methods for identifying if a subject possesses a disease or condition characterized or caused by an immune system deficiency, such as chronic pain or fatigue, long COVID or interstitial cystitis (IC).
Absstract of: US20260273141A1
Disclosed herein are methods of inhibiting sterile alpha and TIR motif-containing protein 1 (SARM1) NADase activity in an axon. The methods can also be used to reduce or delay degeneration in an axon, treat or prevent degeneration of an injured axon, enhance fusion of one or more severed axons, and delay degeneration of one or more fused axons, as well as treat a neurological nerve injury or a neurodegenerative disease in a subject in need thereof using a SARM 1 inhibitor.
Absstract of: EP4807366A2
0001 The present disclosure relates to methods, systems, and devices for performing analyses of biological nanoparticles. More specifically, the present disclosure relates to methods, systems, and devices for performing single biological nanoparticle size determination on a sample while the biological nanoparticle is in transit through a microfluidic chip. In other aspects, the present disclosure relates to methods, systems, and devices for selectively capturing biological nanoparticles on a coated planar surface, the capturing being facilitated by centrifugation.
Absstract of: WO2025099457A2
The invention relates to methods of analysing one or more protein complexes in body fluid samples using ultra-sensitive techniques such as single molecule pulldown. The methods find particular use in detecting protein complex biomarkers for the detection or diagnosis of neurodegenerative disorders. The invention also relates to novel combination biomarkers.
Absstract of: WO2025049921A1
The present disclosure provides a near full-length long read AIRR-seq (FLAIRR-Seq) method that utilizes targeted amplification by 5' rapid amplification of cDNA ends (RACE), combined with single molecule, real-time sequencing to generate highly accurate immunoglobulin (Ig) heavy chain and light chain transcripts.
Nº publicación: JP2026531399A 16/09/2026
Applicant:
スリーチトラティルナルインスティテュートフォーメディカルサイエンシズアンドテクノロジー
Absstract of: WO2025041169A1
The present invention provides a kit, a device and an in-vitro assay based on a nanozyme-based lateral flow assay utilizing para-phenylenediamine of optimal concentration 0.1mM to 10mM as a chromogenic substrate for catalytically active aptamer-conjugated gold-nanozyme, which enhances sensitivity. The chromogenic substrate produces a robust brown color upon oxidation by catalytically active nanomaterial. The brown color remains stable for weeks and presents high contrast against the background. This overcomes the limitations of ordinary LFA in detecting analytes present at critical levels that are below microgram per milliliter, often resulting in false negative results. This provides a versatile and high-sensitive point-of-care diagnostic technique for rapid screening of infectious disease antigens and the detection of biomarkers for diseases such as cancer, cardiac and neurodegenerative diseases.
BOPI
Electronic site
